Nordic Nanovector: European Patent Granted for Betalutin or Humalutin in Combination With Anti-CD20 Antibodies for Treating NHL
Advertisement
Nordic Nanovector ASA announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma (NHL). The same patent has also been issued in Japan, China, Australia, Hong Kong, Israel, Russia and Singapore while the patent is pending in USA, Brazil, Canada, Indonesia, India, Korea, Mexico, New Zealand, Philippines, Ukraine and South Africa.
This patent is a result of Nordic Nanovector's continued focus on securing intellectual property rights on its pipeline of novel CD37-targeting drug candidates.
Patents covering Betalutin® and Humalutin®, as well as their medical applications have already been granted in Europe, USA, Canada, China, Hong Kong, Australia, Indonesia, Israel, Japan, Korea, Mexico, New Zealand, Philippines, Russia, Singapore, Ukraine and South Africa. India, Brazil and Thailand are expected to be granted soon.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers
Sinochem To Acquire Butachlor and Alachlor Businesses In Certain Asian Countries And India From Monsanto
NextPharma inaugurates new production facility for liquid pharmaceuticals in Limay, France - "This project reflects our commitment to bringing the production of essential medicines back to France..."
Camouflage mechanism of cancer cells in Hodgkin's lymphoma decoded - Curt Meyer Memorial Prize for Dr. Stephan Mathas and Dr. Martin Janz
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
European biotech industry identifies the real culprits causing food price rises
NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12
Key molecular interactions of the ZMapp anti-Ebola virus cocktail identified
4SC Announces Clinical Advancements in its Oncology Pipeline
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies
Why European Colonization Drove the Blue Antelope to Extinction - International team of scientists and start-up Colossal Biosciences decode the DNA of the bluebuck using state-of-the-art computer analysis software
